Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 1001 - 1050Interventions to Improve Skin Cancer Surveillance in Childhood Cancer Survivors Who Received Radiotherapy
In a study (Advancing Survivors Knowledge; ASK) reported in the Journal of Clinical Oncology, Geller et al found that three patient- and patient/physician-based interventions to improve skin cancer surveillance among childhood cancer survivors treated with radiotherapy resulted in increased rates...
Trends in Stage, Treatment, and Outcomes in Rectal Adenocarcinoma in the United States: 2004 to 2019
In a retrospective, observational case series study reported in JAMA Oncology, Emile et al identified changes in the stage at diagnosis, treatments, and outcomes in U.S. patients with rectal adenocarcinoma diagnosed between 2004 and 2019. Study Details The study used National Cancer Database data...
Addition of Ultrasound to DBT for Breast Cancer Screening in Patients With Dense Breasts
In the DBTUST study reported in the Journal of Clinical Oncology, Berg et al found that the addition of screening ultrasound to digital breast tomosynthesis (DBT) improved detection of cancer in patients with dense breasts—but also increased the rate of false-positive findings. Study Details In the ...
Addition of Veliparib to Cisplatin in Advanced Triple-Negative Breast Cancer With BRCA-Like and Non–BRCA-Like Phenotype
In a phase II trial (S1416) reported in The Lancet Oncology, Rodler et al found that the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to cisplatin significantly improved progression-free survival in patients with germline BRCA1/2 wild-type advanced triple-negative breast...
Ibrutinib in the First-Line Treatment of Chronic GVHD
As reported in the Journal of Clinical Oncology by Miklos et al, the phase III iNTEGRATE trial showed no benefit of the addition of ibrutinib to prednisone in the first-line treatment of moderate or severe chronic graft-vs-host disease (GVHD) after allogeneic hematopoietic cell transplantation....
Accelerated Partial-Breast Irradiation vs Whole-Breast Irradiation: Long-Term Cosmetic Results and Toxicity
As reported in the Journal of Clinical Oncology by Meduri et al, a 5-year analysis from the phase III IRMA trial has shown higher rates of adverse cosmesis and some late toxicities with external-beam accelerated partial-breast irradiation (APBI) vs whole-breast irradiation (WBI) in women with stage ...
Lenvatinib and Pembrolizumab in Previously Treated Patients With Advanced Endometrial Carcinoma: Update of Study 111/KEYNOTE-146
In an analysis reported in the Journal of Clinical Oncology, Vicky Makker, MD, and colleagues provided updated findings from the phase Ib/II Study 111/KEYNOTE-146 trial of lenvatinib and pembrolizumab in previously treated patients with advanced endometrial carcinoma. The study supported the...
Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
In a phase II study (FOENIX-CCA2) published in The New England Journal of Medicine, Lipika Goyal, MD, and colleagues found that the next-generation, covalently binding FGFR1-4 inhibitor futibatinib showed activity in previously treated patients with unresectable or metastatic FGFR2-altered...
Tremelimumab-actl in Combination With Durvalumab for Unresectable Hepatocellular Carcinoma
On October 21, 2022, tremelimu-mab-actl was approved by the U.S. Food and Drug Administration (FDA) for use in combination with durvalumab in the treatment of unresectable hepatocellular carcinoma.1 Supporting Efficacy Data Approval was based on a comparison of overall survival in the...
Risk of Contralateral Breast Cancer Among Patients With Invasive Breast Cancer and Various Germline Pathogenic Variants
In a study reported in the Journal of Clinical Oncology, Yadav et al estimated the risk of contralateral breast cancer among patients with invasive breast cancer and germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. Study Details The study population consisted of 15,104...
Appendectomy With or Without Hemicolectomy for 1- to 2-cm Appendiceal Neuroendocrine Tumors
In a European retrospective cohort study reported in The Lancet Oncology, Nesti et al found evidence that right-sided hemicolectomy is not indicated in patients who had complete resection, via appendectomy, of appendiceal neuroendocrine tumors (NETs) measuring 1 to 2 cm. As stated by the...
Neoadjuvant Gemcitabine/Cisplatin in High-Risk Upper Tract Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Coleman et al found that neoadjuvant split-dose gemcitabine and cisplatin produced a high rate of pathologic response in patients with high-risk localized upper tract urothelial carcinoma. The investigators also showed that...
MRI-Guided vs CT-Guided SBRT for Localized Prostate Cancer
In the single-center phase III MIRAGE trial reported in JAMA Oncology, Amar U. Kishan, MD, and colleagues found that use of margin reduction with magnetic resonance imaging (MRI)-guided stereotactic body radiotherapy (SBRT) resulted in significantly reduced acute genitourinary (GU) and...
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide in Maintenance Therapy After ASCT in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Dominik Dytfeld, MD, PhD, and colleagues, an unplanned interim analysis of the phase III ATLAS trial has shown improved progression-free survival with carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide alone as maintenance after autologous stem...
Frequency and Dosage of Radiotherapy in Chemoradiotherapy for Limited-Stage SCLC
As reported in the Journal of Clinical Oncology by Jeffrey Bogart, MD, and colleagues, the phase III CALGB 30610/RTOG 0538 trial has shown no significant difference in overall survival with 70-Gy once-daily vs 45-Gy twice-daily radiotherapy in a chemoradiotherapy regimen for limited-stage small...
ROBO2 as a Novel Susceptibility Gene for Risk of Anthracycline-Related Cardiomyopathy in Childhood Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Wang et al found that a single-nucleotide polymorphism (SNP) in ROBO2 was associated with an increased risk of cardiomyopathy among childhood cancer survivors receiving higher cumulative anthracycline doses. As stated by the investigators,...
Long-Term Follow-up of Combined TEXT and SOFT Trials
As reported in the Journal of Clinical Oncology by Olivia Pagani, MD, and colleagues, 13-year follow-up in a combined analysis of the phase III TEXT and SOFT trials has shown continued disease-free survival and distant recurrence–free interval benefit—but no overall survival benefit—with exemestane ...
Neoadjuvant Pembrolizumab in Localized MSI-H/dMMR Solid Tumors
In a single-center phase II trial reported in the Journal of Clinical Oncology, Ludford et al found that neoadjuvant pembrolizumab produced a high pathologic complete response rate and radiographic objective response rate in patients with localized microsatellite instability–high/mismatch...
Circulating Tumor DNA Profiling and Outcomes in CNS Lymphoma
In a German study reported in the Journal of Clinical Oncology, Mutter et al found that circulating tumor DNA (ctDNA) identified prior to and during treatment was associated with poorer outcomes in patients with central nervous system (CNS) lymphoma. Study Details The study included 92 patients...
Effect of Medicaid Expansion on Survival for Young Adults With Cancer
In a study reported in the Journal of Clinical Oncology, Ji et al found that Medicaid expansion through the Affordable Care Act (ACA) has been associated with improved 2-year survival among young adults with cancer, with greater benefits observed in patients with breast cancer, those with stage IV...
Subcutaneous Epcoritamab for Relapsed or Refractory Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Catherine Thieblemont, MD, PhD, and colleagues, findings in a dose-expansion cohort of the phase I/II EPCORE NHL-1 study indicated high activity of the subcutaneous CD3 x CD20 T-cell–engaging bispecific antibody epcoritamab in patients with...
Trends in U.S. E-Cigarette Sales, Price, and Nicotine Strength
In a study reported in Nicotine & Tobacco Research, Ali et al found that U.S. sales of e-cigarettes have increased, marked by sales of products with higher nicotine strength, and that prices have increased for products with lower nicotine strength while decreasing or not significantly changing...
Risk Factors for Local Failure After Chemoradiation and MRI-Guided Brachytherapy for Locally Advanced Cervical Cancer
In a study reported in the Journal of Clinical Oncology, Schmid et al identified risk factors for local failure in patients receiving chemoradiation and magnetic resonance imaging (MRI)-guided brachytherapy for locally advanced cervical cancer. Study Details The study used data from the EMBRACE-I...
Cancer Survival in Africa, Central and South America, and Asia: SURVCAN-3 Study
In the population-based SURVCAN-3 study reported in The Lancet Oncology, Soerjomataram et al identified cancer survival rates in 32 countries in Africa, Central and South America, and Asia. They found that disparities for many cancer types reflect the standing of countries according to the Human...
Outcomes in Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation–Sparing Curative-Intent Treatment
In a study reported in the Journal of Clinical Oncology, Erker et al identified factors associated with better postrelapse survival among infants and young children with medulloblastoma relapsing after initial craniospinal irradiation (CSI)-sparing curative-intent treatment. These factors included...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
In the phase I/II CodeBreaK 100 trial reported in The New England Journal of Medicine, John H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor sotorasib showed activity in previously treated patients with advanced pancreatic cancer and a KRAS G12C mutation. Study Details In the...
POLLUX Trial Final Overall Survival Analysis: Addition of Daratumumab to Lenalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the pivotal phase III POLLUX trial has shown a significant benefit with the addition of daratumumab to lenalidomide and dexamethasone after a median follow-up of...
Genomic Profile to Identify Candidates for Omission of Local Adjuvant Radiation Among Patients With Breast Cancer
In a study reported in the Journal of Clinical Oncology, Sjöström et al identified a 16-gene signature—Profile for the Omission of Local Adjuvant Radiation, or POLAR—that predicted low likelihood of benefit from adjuvant radiotherapy in preventing locoregional recurrence in patients with...
Effect of Adjuvant Chemotherapy on Survival in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy
In a retrospective matched-cohort study reported in JAMA Oncology, Sugawara et al found that receipt of adjuvant chemotherapy improved survival vs no adjuvant chemotherapy in patients with pancreatic adenocarcinoma who received curative-intent surgery following multiagent neoadjuvant chemotherapy....
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation
In the phase I/II KRYSTAL-1 trial reported in The New England Journal of Medicine, Rona Yaeger, MD, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients with metastatic colorectal cancer and mutated KRAS...
First-Line Atezolizumab Plus Bevacizumab in Metastatic Nonsquamous NSCLC With High Tumor Mutation Burden
In a Spanish phase II trial reported in JAMA Oncology, Mariano Provencio, MD, PhD, and colleagues found that the combination of atezolizumab and bevacizumab was active in the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation...
Risk-Reducing Medication in Patients With High-Risk, ER-Positive Breast Cancer: Benefits and Harms
In a study reported in the Journal of Clinical Oncology, Jayasekera et al identified the benefits and harms of using risk-reducing medication in addition to screening in patients with high-risk, estrogen receptor (ER)-positive breast cancer. As stated by the investigators, “Recent studies,...
KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC
As reported in the Journal of Clinical Oncology by Qin et al, the phase III KEYNOTE-394 trial showed overall and progression-free survival benefits with pembrolizumab vs placebo in previously treated Asian patients with advanced hepatocellular carcinoma (HCC). Study Details The double-blind trial...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Crizotinib Combined With Chemotherapy in Pediatric ALK-Positive Anaplastic Large Cell Lymphoma
As reported in the Journal of Clinical Oncology by Lowe et al, findings in an arm of the Children’s Oncology Group phase II ANHL12P1 trial (arm CZ) showed high event-free and overall survival rates with the addition of crizotinib to chemotherapy in newly diagnosed pediatric patients with...
Endoscopic Surveillance With Systematic Random Biopsy vs Targeted Biopsy for Early Diagnosis of Hereditary Diffuse Gastric Cancer
In a UK study reported in The Lancet Oncology, Lee et al found that systematic random biopsies were more likely than endoscopically targeted biopsies to first detect signet ring cell carcinoma during endoscopic surveillance of individuals meeting testing criteria for hereditary diffuse gastric...
Late Mortality, Subsequent Malignant Neoplasms, and Chronic Health Conditions Among Survivors of Neuroblastoma Diagnosed During Infancy
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Friedman et al found low rates of late mortality and subsequent malignant neoplasms in survivors of neuroblastoma treated in infancy. The risk of severe chronic health conditions decreased during...
Adjuvant Endocrine Therapy and Ovarian Suppression for Premenopausal Patients With Hormone Receptor–Positive Breast Cancer: 12-Year Results of the SOFT Trial
As reported in the Journal of Clinical Oncology by Prudence A. Francis, MD, and colleagues, 12-year results of the phase III SOFT trial show a maintained disease-free survival benefit with the addition of ovarian function suppression to adjuvant tamoxifen in premenopausal patients with hormone...
Risk Prediction Model for Contralateral Breast Cancer in BRCA Carriers With Breast Cancer
In a Chinese study reported in the Journal of Clinical Oncology, Sun et al developed a risk prediction model (BRCA-CRisk) to assess the risk of contralateral breast cancer in patients with breast cancer and BRCA1/2 pathogenic/likely pathogenic variants. Study Details The model was developed in a...
Risk of Incident Lung Cancer in Individuals With Clonal Hematopoiesis
In a study reported in the Journal of Clinical Oncology, Tian et al found that clonal hematopoiesis was associated with an increased risk of subsequent lung cancer, independent of known risk factors. Study Details Two nested case-control studies were performed. One included 832 incident lung cancer ...
Hypofractionated 3-Week Course of Preoperative Radiotherapy for Soft-Tissue Sarcomas
In a single-center phase II trial (HYPORT-STS) reported in The Lancet Oncology, Guadagnolo et al found that a hypofractionated 3-week course of preoperative radiotherapy was safe in patients with soft-tissue sarcomas and may serve as an alternative to conventionally fractionated radiotherapy in...
Racial/Ethnic Disparities in Recommendations for Surgical Resection of Newly Diagnosed Brain Tumors
In a U.S. registry-based cohort study reported in The Lancet, Butterfield et al found that Black patients were significantly more likely than White patients to receive recommendations against surgical resection for multiple types of newly diagnosed brain tumors. Study Details The study included...
Silicone Film to Prevent Acute Radiation Dermatitis in Patients With Breast Cancer
In a Canadian phase III trial reported in the Journal of Clinical Oncology, Behroozian et al found that the use of Mepitel film—a silicone-based polyurethane film dressing—significantly reduced the incidence of grade 2 or 3 acute radiation dermatitis vs usual care in at-risk women receiving...
FORTE Trial of Carfilzomib-Containing Induction, Consolidation, and Maintenance in Newly Diagnosed Multiple Myeloma: Subgroup Analysis by Cytogenetic Risk
In a prespecified analysis of the Italian phase II FORTE trial reported in The Lancet Oncology, Mina et al identified outcomes associated with the number of high-risk cytogenetic abnormalities (HRCAs) across treatment groups receiving carfilzomib-containing induction, consolidation, and maintenance ...
Preexisting Autoimmune Disease and Risk for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy for Cancer
In a single academic hospital network retrospective case-control study reported in JACC: CardioOncology, Lee et al found that patients with vs without preexisting autoimmune disease who received immune checkpoint inhibitor therapy for cancer had significantly increased risk of cardiovascular...
Associations Between CDH1 Germline Variants and Hereditary Diffuse Gastric Cancer Syndrome Cancer Phenotypes
In a study reported in The Lancet Oncology, Garcia-Pelaez and colleagues found that presence of germline truncating pathogenic variants or likely pathogenic variants of CDH1 were associated with hereditary diffuse gastric cancer (HDGC) tumor risk syndrome–related cancer phenotypes (lobular breast...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
Concomitant and Sequential Nivolumab, Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Bröckelmann et al, final results of the German Hodgkin Study Group phase II NIVAHL trial indicate nearly 100% progression-free survival and 100% overall survival at 3 years among patients with early-stage unfavorable classical Hodgkin lymphoma...
Cardiovascular Events Before and After Initiation of Immune Checkpoint Inhibitor Therapy for Cancer: Agreement Between ICD-Coded and -Adjudicated Events
In a study reported in JACC: CardioOncology, Kondapalli et al found that cardiovascular events common in the general population were observed both prior to and after initiation of immune checkpoint inhibitor therapy for cancer; myocarditis was more common posttreatment, but infrequent. Agreement...
